New Approaches for the Detection and Characterization of Alpha-Fetoprotein Epitope Variants

Karamova, E.R.; Yazova, A. K.; Yakimenko, E.F.; Gussev, A.I.; Абелев, Г. И.

doi:10.1159/000070654

Cited by 5 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TD-2 Workshop went further in defining the relationship between the epitope groups reaching a consensus of 5 major domains. As with many glycoprotein tumor markers, glycosylation variants continue to affect the measurement [10,11], and influence the diagnostic capacity of AFP. Further developments in this area may represent a possible subject for future AFP Workshops.…”

Section: Td-2 Afpmentioning

confidence: 99%

Tumor Marker Workshops

Rye¹,

Nustad²,

Stigbrand³

2003

Tumor Biol

View full text Add to dashboard Cite

Since 1996, the nine ISOBM Workshops have so far characterized more than 300 monoclonal antibodies to a variety of tumor markers that include CA125, AFP, PSA, MUC1, Cytokeratins, Sialyl Le^a, hCG, CEA, ALP, and more recently SCC, and S100. Besides the basic characterization of antibodies and their epitope configurations, several workshops have also addressed specific problems associated with multiple antigen variants. These workshops have been able to make significant advances well beyond those possible through any normal collaboration study. The data and impact of these workshops with their summary reports are reviewed.

show abstract

Section: Td-2 Afpmentioning

confidence: 99%

Tumor Marker Workshops

Rye¹,

Nustad²,

Stigbrand³

2003

Tumor Biol

View full text Add to dashboard Cite

show abstract

Therapeutic use of human alpha‐fetoprotein in clinical patients: Is a cancer risk involved?

Mizejewski

2010

Intl Journal of Cancer

View full text Add to dashboard Cite

Conformational Fingerprinting Using Monoclonal Antibodies (on the Example of Angiotensin I-Converting Enzyme-ACE)

Danilov

2017

Mol Biol

View full text Add to dashboard Cite

⎯During the past 30 years my laboratory has generated 40+ monoclonal antibodies (mAbs) directed to structural and conformational epitopes on human ACE as well as ACE from rats, mice and other species. These mAbs were successfully used for detection and quantification of ACE by ELISA, Western blotting, flow cytometry and immunohistochemistry. In all these applications mainly single mAbs were used. We hypothesized that we can obtain a completely new kind of information about ACE structure and function if we use the whole set of mAbs directed to different epitopes on the ACE molecule. When we finished epitope mapping of all mAbs to ACE (and especially, those recognizing conformational epitopes), we realized that we had obtained a new tool to study ACE. First, we demonstrated that binding of some mAbs is very sensitive to local conformational changes on the ACE surface-due to local denaturation, inactivation, ACE inhibitor or mAbs binding or due to diseases. Second, we were able to detect, localize and characterize several human ACE mutations. And, finally, we established a new concept-conformational fingerprinting of ACE using mAbs that in turn allowed us to obtain evidence for tissue specificity of ACE, which has promising scientific and diagnostic perspectives. The initial goal for the generation of mAbs to ACE 30 years ago was obtaining mAbs to organ-specific endothelial cells, which could be used for organ-specific drug delivery. Our systematic work on characterization of mAbs to numerous epitopes on ACE during these years has lead not only to the generation of the most effective mAbs for specific drug/gene delivery into the lung capillaries, but also to the establishment of the concept of conformational fingerprinting of ACE, which in turn gives a theoretical base for the generation of mAbs, specific for ACE from different organs. We believe that this concept could be applicable for any glycoprotein against which there is a set of mAbs to different epitopes.

show abstract

New Approaches for the Detection and Characterization of Alpha-Fetoprotein Epitope Variants

Cited by 5 publications

References 19 publications

Tumor Marker Workshops

Tumor Marker Workshops

Therapeutic use of human alpha‐fetoprotein in clinical patients: Is a cancer risk involved?

Conformational Fingerprinting Using Monoclonal Antibodies (on the Example of Angiotensin I-Converting Enzyme-ACE)

Contact Info

Product

Resources

About